Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

Background: Pneumococcal disease remains a public health priority in adults. Previous studies have suggested that administration of pneumococcal polysaccharide vaccine or pneumococcal conjugate vaccine within three years following receipt of PPV23 was associated with increased reactogenicity and red...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Hum Vaccin Immunother
Prif Awduron: Peterson, James T., Stacey, Helen L., MacNair, John E., Li, Jianing, Hartzel, Jonathan S., Sterling, Tina M., Benner, Patrice, Tamms, Gretchen M., Musey, Luwy K.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Taylor & Francis 2018
Pynciau:
Research Paper
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6605723/
https://ncbi.nlm.nih.gov/pubmed/30427749
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2018.1532250
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg